Antidiabetic medications and chronic kidney disease

The relationship between antidiabetic medications and chronic kidney disease has profoundly changed the treatment of type 2 diabetes mellitus, because the kidney is no longer regarded merely as a target organ to be monitored once damage is already evident, but as one of the principal determinants of therapeutic choice from the earliest stages of care. For a long time, the clinical problem was interpreted mainly in terms of dose adjustment and safety: which drugs to avoid as glomerular filtration declined and which to use cautiously to reduce the risk of accumulation, hypoglycemia, or toxicity. Today, this approach is insufficient. The correct question is not only which drugs remain usable in nephropathy, but which drugs can slow the progression of kidney damage, reduce the likelihood of advanced kidney failure, limit the loss of glomerular function, and at the same time protect the cardiovascular system.

In type 2 diabetes, chronic kidney disease is not a minor accompanying comorbidity. It is one of the most frequent and prognostically important complications and is closely intertwined with cardiovascular risk, because albuminuria, reduced estimated glomerular filtration rate, hypertension, volume overload, neurohormonal activation, inflammation, and endothelial dysfunction mutually reinforce one another in a complex cardiorenal syndrome. Modern selection of antidiabetic medication in patients with nephropathy can therefore no longer be guided by glycated hemoglobin alone. It must integrate kidney protection, cardiovascular protection, metabolic safety, hypoglycemic risk, effects on body weight, and compatibility with the level of residual kidney function. The current hierarchy of drug classes in diabetes associated with chronic kidney disease arises from this conceptual transition.

The presence of chronic kidney disease modifies treatment of type 2 diabetes on several levels simultaneously. The first is pharmacokinetic, because reduced glomerular filtration alters the elimination, systemic exposure, and duration of action of several molecules, requiring review of doses, thresholds for use, and the risk of adverse effects. The second is pathophysiologic, because the diseased kidney actively participates in progression of complicated diabetes by amplifying glomerular hypertension, proteinuria, anemia, sodium retention, endothelial dysfunction, and cardiovascular vulnerability. The third is prognostic, because a patient with diabetes and chronic kidney disease has a much higher risk not only of progression to advanced kidney failure, but also of cardiovascular death, heart failure, and hospitalization.

For many years, the therapeutic approach was mainly defensive. Clinicians primarily asked which drugs should be discontinued as kidney function worsened. This view was superseded when cardiorenal trials demonstrated that some drug classes are not only compatible with diabetic kidney disease, but can modify the course of kidney disease itself. This transition has enormous significance: the kidney is no longer merely a limitation on therapy, but an active therapeutic target.

Chronic kidney disease also changes the risk of hypoglycemia. As kidney function declines, clearance of some drugs decreases and insulin metabolism is altered, while renal gluconeogenesis, which contributes to defense against hypoglycemia, may also be impaired. This makes secretagogues and insulin more hazardous, particularly in older, frail, or malnourished patients and in those with variable food intake. Hypoglycemic safety consequently becomes an even more important criterion than in patients with diabetes without nephropathy.

Finally, chronic kidney disease requires a distinction between drugs chosen for glycemic control and drugs chosen for kidney protection. This distinction is decisive. A class may lose part of its glucose-lowering efficacy as glomerular filtration declines while still retaining a substantial benefit on progression of nephropathy. It is precisely this dissociation between glycemic and renal effects that has changed modern algorithms.

In patients with type 2 diabetes mellitus, renal assessment cannot be reduced to serum creatinine alone. Drug selection requires at least two fundamental dimensions: the estimated glomerular filtration rate and albuminuria. Estimated filtration provides an assessment of clearance capacity and guides eligibility, dose, and accumulation risk for different therapies. Albuminuria, by contrast, is not only an indicator of glomerular injury, but a strong renal and cardiovascular prognostic marker. A patient with relatively preserved filtration but marked albuminuria may have a substantial risk of progression, often greater than a superficial interpretation of creatinine would suggest.

Correct assessment therefore requires simultaneous consideration of kidney function, degree of albuminuria, the trajectory of filtration over time, blood pressure control, cardiovascular history, the presence of heart failure, treatment with renin–angiotensin–aldosterone system inhibitors, volume status, biological age, nutritional status, and hypoglycemic risk. In this setting, an antidiabetic medication is never an isolated choice. It should be integrated into a broader cardiorenal strategy.

It should also be remembered that nephropathy in a patient with diabetes does not automatically correspond to classic albuminuric diabetic kidney disease. Phenotypes with reduced filtration and modest albuminuria, mixed conditions with nephroangiosclerosis, concomitant nephropathies, and ischemic or toxic injury also exist. This is important because pharmacologic treatment should be guided by overall renal risk rather than by a stereotyped view of diabetic damage.

In practical terms, what truly matters before prescribing is knowing whether the patient has documented chronic kidney disease, how far filtration has declined, whether significant albuminuria is present, whether heart failure coexists, whether hypoglycemic episodes occur, whether conditions that favor dehydration or ketoacidosis are present, and whether treatment should be selected primarily for kidney protection, glycemic control, or both goals together.

• Always assess estimated glomerular filtration rate and albuminuria.
• Distinguish the need for kidney protection from the need for glucose lowering alone.
• Consider the kidneys, heart, hypoglycemic risk, and volume status together.

Sodium-glucose cotransporter 2 inhibitors are the class that has most profoundly changed the relationship between antidiabetic therapy and chronic kidney disease. Their initial mechanism is well known: they reduce proximal tubular reabsorption of glucose and sodium, inducing glycosuria and natriuresis. Their nephrologic value, however, is not explained solely by lower blood glucose. The central mechanism is restoration of more physiologic tubuloglomerular feedback, with reduction of hyperfiltration and intraglomerular pressure, one of the major drivers of progressive kidney damage in diabetes.

This intrarenal hemodynamic action is accompanied by favorable effects on extracellular volume, blood pressure, body weight, cardiorenal congestion, and metabolic stress. Clinically, these drugs can slow the loss of kidney function and reduce the risk of major renal events to an extent that goes far beyond their glucose-lowering effect. This is precisely why, even as filtration declines and their effect on blood glucose attenuates, the rationale for continuing them may remain very strong.

Major renal trials have consolidated this position. CREDENCE demonstrated that canagliflozin significantly reduced the risk of renal progression and cardiovascular events in patients with type 2 diabetes and albuminuric kidney disease. DAPA-CKD extended the paradigm by showing that dapagliflozin reduced renal events and mortality in a broader population with chronic kidney disease, including individuals without diabetes. EMPA-KIDNEY further strengthened the concept in a population heterogeneous in filtration levels and albuminuria. These results made sodium-glucose cotransporter 2 inhibitors a cornerstone of modern kidney protection.

In clinical practice, this class should be considered early in patients with type 2 diabetes and chronic kidney disease, provided there are no contraindications or conditions that make its use hazardous. Clinicians must, however, understand the practical limitations: genital mycotic infections, risk of volume depletion in vulnerable individuals, the possibility of euglycemic diabetic ketoacidosis in selected settings, and the need for temporary discontinuation during acute illness, prolonged fasting, surgery, or significant catabolic states.

Their current therapeutic significance is therefore twofold. On the one hand, they lower blood glucose when filtration permits. On the other, and more profoundly, they reduce the likelihood that the patient will enter a more rapid trajectory of irreversible renal decline. This is why the clinical question today is not whether a patient with nephropathy can take a sodium-glucose cotransporter 2 inhibitor, but whether there is a valid reason not to offer one.

Glucagon-like peptide 1 receptor agonists occupy a different but increasingly important position from sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Their most immediate advantage is well known: a substantial reduction in glycated hemoglobin, weight loss, low hypoglycemic risk, and, for some molecules, documented cardiovascular benefit. This profile is particularly attractive in patients with nephropathy because it improves metabolic control without substantially increasing hypoglycemic risk.

For a long time, their renal role was considered mainly indirect, mediated by improvements in blood glucose, body weight, blood pressure, and metabolic inflammation. The picture changed, however, as more robust data accumulated. Several cardiovascular outcome trials of the class had already shown favorable signals for albuminuria and progression of kidney damage. Subsequently, the FLOW trial with semaglutide provided specifically renal evidence, showing a reduction in clinically relevant renal outcomes and cardiovascular death in patients with type 2 diabetes and chronic kidney disease.

This result does not replace the role of sodium-glucose cotransporter 2 inhibitors, but expands the kidney-protective strategy. In a patient with chronic kidney disease, obesity, a need for substantial glucose lowering, and high cardiovascular risk, a glucagon-like peptide 1 receptor agonist can add important metabolic and prognostic benefit, particularly when glycemic control remains inadequate or other classes are not tolerated.

Selection of the individual molecule should consider the available evidence, gastrointestinal tolerability, the need for gradual titration, the presence of significant gastroparesis, acceptance of injectable or oral therapy, and nutritional status. In patients with advanced chronic kidney disease and poor appetite, for example, weight loss is not always an absolute advantage and should be interpreted in the real clinical context.

The current role of these drugs in diabetes with nephropathy is therefore that of a class combining potent metabolic efficacy, cardiovascular benefit, and growing renal relevance, particularly as part of a multitarget strategy.

Metformin retains an important position in treatment of type 2 diabetes mellitus even when chronic kidney disease is present, but its role should be interpreted correctly. It is not the principal kidney-protective drug in the modern sense, yet remains a highly useful therapeutic foundation because of its efficacy, low hypoglycemic risk, low cost, and extensive experience of use. In patients with preserved or moderately reduced kidney function, metformin often remains part of background therapy.

The critical point is that its management in nephropathy should not be simplistic. It should no longer be considered automatically contraindicated as soon as mild or moderate renal deterioration appears, but used in proportion to glomerular filtration and overall clinical risk. Caution arises primarily from concern about lactic acidosis, a rare but potentially serious event whose risk increases with advanced kidney failure, tissue hypoxia, sepsis, unstable heart failure, severe liver disease, or acute conditions involving dehydration and reduced perfusion.

Metformin is therefore often appropriate as background therapy in patients with nonadvanced chronic kidney disease, but requires periodic reassessment of glomerular filtration, temporary discontinuation during acute phases, and clear counseling about so-called sick days, namely days of illness during which the risk of accumulation and metabolic complications increases.

Conceptually, metformin in patients with nephropathy is no longer the drug that alone defines the therapeutic strategy. Rather, it is a useful platform to be integrated with classes offering genuine renal and cardiorenal protection. This explains why its practical centrality remains substantial, while its prognostic centrality is now more relative than in the past.

Dipeptidyl peptidase 4 inhibitors retain a selective role in patients with type 2 diabetes and chronic kidney disease. Their profile is characterized by good tolerability, weight neutrality, low hypoglycemic risk, and the convenience of oral administration. Their glucose-lowering efficacy is moderate, however, and, most importantly, they do not carry the renal and cardiovascular prognostic weight of newer classes. In patients with nephropathy, they may be useful when simplicity and hypoglycemic safety are sought, but they are not the first choice when the main objective is to slow progression of kidney disease.

Sulfonylureas become more problematic as kidney function worsens. The main risk is hypoglycemia, which may be more prolonged, more severe, and more difficult to manage in chronic kidney disease. This reflects both reduced clearance of the drug or its metabolites and a lower capacity of the body to compensate for falling blood glucose. In settings with limited financial resources or lack of access to other classes, sulfonylureas may still have a role, but their use in nephropathy requires far greater caution than in patients with normal kidney function.

Insulin remains essential in patients with chronic kidney disease, particularly when hyperglycemia is marked, beta-cell reserve is reduced, or control with other drugs is inadequate. In nephropathy, however, insulin metabolism changes and insulin clearance decreases, increasing hypoglycemic risk. This does not make insulin inappropriate, but requires more careful titration, closer monitoring, more cautious dose adjustments, and continuous assessment of nutritional status and food intake.

Strategically, the problem with these classes is not that they cannot be used, but that they are not the classes that now best meet the dual objectives of kidney protection and metabolic safety. They therefore remain drugs to be placed within a precise rationale, not used through therapeutic inertia.

Pioglitazone has a narrower but nonzero role in patients with type 2 diabetes and chronic kidney disease. Its potential advantage lies in improving insulin resistance and in certain metabolic effects on adipose tissue, the liver, and glycemic status. From a strictly renal standpoint, however, it is not a reference kidney-protective therapy, and its use should primarily be interpreted in light of the overall metabolic phenotype.

The main limitation in chronic kidney disease is its tendency to cause fluid retention, edema, and possible worsening of heart failure. Because many patients with diabetic kidney disease already have a fragile cardiorenal balance, this substantially reduces the drug’s appeal. In selected individuals with marked insulin resistance, no current or prior heart failure, and no volume overload, pioglitazone may still have a role, but in contemporary practice it is rarely the cornerstone of therapy when chronic kidney disease is present.

Its importance is therefore mainly educational and selective: it reminds us that not all drugs effective on blood glucose are equivalent when the kidney becomes a priority target organ, and that the prognostic value of a molecule depends on the hemodynamic and cardiovascular context in which it is used.

One of the most important changes in recent years is that, in patients with type 2 diabetes and chronic kidney disease, drug selection may be guided more by kidney protection than by the mere intensity of glucose lowering. This principle is crucial. A patient may have glycated hemoglobin that is not dramatically elevated but a very high renal risk because of persistent albuminuria, rapid decline in filtration, or coexisting heart failure. In this setting, the priority is not necessarily to lower glycated hemoglobin as much as possible by any means, but to use drugs that slow progression of kidney disease and reduce the risk of major cardiorenal events.

This is why sodium-glucose cotransporter 2 inhibitors entered modern recommendations even when their glycemic efficacy attenuates. Clinicians must adopt a different logic: the value of a drug does not always correspond to how many tenths of a percentage point it lowers glycated hemoglobin, but to how much it changes the patient’s prognostic trajectory.

The use of glucagon-like peptide 1 receptor agonists follows the same logic, as drugs to be integrated when additional glycemic control, weight reduction, and cardiovascular benefit are needed, with an increasingly relevant renal profile. The modern strategy is therefore often additive rather than competitive: metformin when appropriate, a sodium-glucose cotransporter 2 inhibitor for kidney protection, and subsequent integration of other classes according to obesity, cardiovascular risk, and the glycemic target.

This treatment model also requires overcoming clinical inertia. Waiting for filtration to collapse or albuminuria to become marked before introducing protective drugs means losing part of the therapeutic window. Effective kidney protection is more useful the earlier it is incorporated into a comprehensive strategy.

In patients with chronic kidney disease, practical safety is an essential component of drug selection. The first risk to consider is hypoglycemia, which increases with sulfonylureas and insulin, but may also become clinically relevant because of changes in filtration, reduced food intake, intercurrent infections, or acute deterioration of kidney function. Glucose monitoring and periodic dose review are therefore more important than in patients with diabetes without nephropathy.

The second risk is dehydration or volume depletion, particularly relevant with drugs that promote natriuresis and osmotic diuresis. This does not mean automatically avoiding the most useful classes, but knowing how to use them correctly in older patients, those taking diuretics, those with low blood pressure, or those prone to acute episodes of diarrhea, vomiting, or fever.

The third issue is prevention of euglycemic diabetic ketoacidosis with sodium-glucose cotransporter 2 inhibitors in selected settings. The risk is low but real and requires informing the patient when the drug should be temporarily withheld: prolonged fasting, surgery, severe intercurrent illness, reduced caloric intake, alcohol misuse, or suspected significant catabolism.

Finally, with metformin, the principal issue is knowing when to discontinue it temporarily in conditions that increase the risk of tissue hypoperfusion or acute deterioration of kidney function. All of this falls within modern education on sick days, which in patients with nephropathy is an integral part of treatment rather than a marginal recommendation.

Treatment of patients with type 2 diabetes and chronic kidney disease is rarely limited to monotherapy. The most rational strategy is often a progressive and complementary construction. When filtration permits and no contraindications exist, metformin may remain the foundation. A sodium-glucose cotransporter 2 inhibitor is then added early when the objective is to slow renal progression and reduce cardiorenal risk.

If glycemic control remains inadequate, or if the patient has obesity, high cardiovascular risk, or a need to avoid hypoglycemia, the next most rational step is often a glucagon-like peptide 1 receptor agonist with favorable cardiovascular and, now, renal data. Treatment thereby becomes multidimensional: blood glucose, body weight, kidneys, and heart are addressed simultaneously.

When these strategies are insufficient, or when the patient has severe hyperglycemia, catabolism, or marked exhaustion of beta-cell function, insulin becomes necessary. Even then, however, treatment should not be viewed as an automatic substitution. It is often preferable to maintain drugs that continue to provide renal or cardiovascular benefit, thereby reducing insulin requirements and limiting the risk of weight gain and hypoglycemia.

The correct combination is therefore one that avoids both inertia and the disordered accumulation of molecules. Each addition should have a distinct rationale: kidney protection, additional glycemic efficacy, weight reduction, hypoglycemic safety, or simpler management.

Drug selection in type 2 diabetes associated with chronic kidney disease now has a much broader prognostic significance than in the past. It is not simply a matter of deciding how to control blood glucose in a patient with reduced filtration, but of influencing the rate at which kidney function will be lost, the likelihood of advanced kidney failure, the future need for dialysis, the risk of hospitalization for heart failure, and cardiovascular mortality.

In this new paradigm, drug classes are not equivalent. Some are mainly compatible with chronic kidney disease. Others are genuinely kidney protective. Sodium-glucose cotransporter 2 inhibitors have redefined the very concept of antidiabetic therapy in patients with nephropathy. Glucagon-like peptide 1 receptor agonists have broadened metabolic, cardiovascular, and increasingly renal protection. Metformin remains useful as a foundation when appropriate. Other classes require more selective use.

Prognosis also depends on timeliness. Therapy introduced too late loses part of its potential. Conversely, a strategy initiated early and reassessed regularly can slow the natural history of diabetic kidney disease to a clinically meaningful extent. This makes antidiabetic prescribing in patients with chronic kidney disease a true act of prognostic medicine rather than a simple correction of laboratory values.

In conclusion, the best drug for a patient with type 2 diabetes and chronic kidney disease is not the one that lowers glycated hemoglobin the most in the abstract, but the one that, in that patient’s specific clinical profile, controls blood glucose, reduces hypoglycemic risk, and above all protects the kidneys and the cardiovascular system over the long term.